Introduction
============

Blood platelets play a key role in haemostasis through binding to sites of vascular injury to form a primary haemostatic plug. However, uncontrolled platelet activation is intimately linked to thrombotic events associated with the rupture of atherosclerotic plaques. Controlling inappropriate platelet activation is critical to protecting against thrombotic episodes. Primary inhibitory mechanisms are mediated by endothelial derived-nitric oxide (NO) and prostacyclin (PGI~2~), which stimulate soluble guanylyl cyclase (sGC) and adenylyl cyclase (AC) leading to activation of cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP)-mediated signaling pathways, respectively ([@B39]). cAMP/cGMP-dependent protein kinases phosphorylate target proteins that are associated with controlling platelet activation while multiple phosphodiesterases (PDEs) hydrolyse cyclic nucleotides to terminate signaling. The cAMP and cGMP signaling pathways have overlapping target specificity, but also synergise indicating diversity in target selection. In many cell types the enzymes that generate, propagate and terminate cAMP signaling are organized into restricted microdomains that focus the activity of the cAMP signaling cascade to specific substrates ([@B41]; [@B37]; [@B40]). This compartmentalisation of cAMP signaling allows stimulus-specific control of distinct cell functions. Given the central importance of cAMP signaling to the control of platelet function, surprisingly little is known about the molecular mechanisms that coordinate the synthesis and hydrolysis of cAMP, the precise molecular targets of cAMP signaling and how these targets contribute to the control of specific platelet functions. In this perspective article, we provide an overview of cAMP signaling and examine emerging concepts of compartmentalization in platelets.

The cAMP Signaling System in Platelets
======================================

The binding of PGI~2~, prostaglandin E~1~ and adenosine to their receptors on platelets leads to the elevation of intracellular cAMP through the activation of AC. While there are nine membrane bound isoforms of AC, human platelets express only AC3 and AC5/6 ([@B32]; [@B4]; [@B7]). The roles of these individual AC isoforms and whether they are linked to specific receptors or stimuli are unknown. Increased cAMP leads to the activation of protein kinase A (PKA), the foremost effector of cAMP signaling in platelets. The holoenzyme of PKA is an inactive heterotetramer composed of two regulatory (R) and two catalytic (C) subunits. Platelets express all the known isoforms of the regulatory and catalytic subunits (RIα, RIβ, RIIα, RIIβ, Cα, Cβ, and Cγ) ([@B26]; [@B4]), indicating that platelets likely possess multiple variations of the two PKA subtypes, PKA-I and PKA-II, which have distinct biochemical properties. The binding of four cAMP molecules to their binding sites on PKA, result in a conformational change unleashing the catalytic subunit and consequently the phosphorylation of adjacent protein substrates. To date sixteen substrates have been characterized in platelets, although a recent proteomic study suggests that over 100 substrates may be present ([@B2]). These substrates can be categorized into proteins involved in regulating: (i) shape change (actin polymerization), (ii) calcium signaling, or (iii) integrin activation ([@B36]; [@B29]). The phosphorylation of these proteins by PKA is proposed to be the primary mechanism by which prostacyclin modulate platelet activation. As platelet pass through the circulation they are marginalized to the periphery of the vessel facilitating constant exposure to endothelial-derived PGI~2~. Therefore it is likely that the default status of platelets in the circulation is one of elevated cAMP and activated PKA, which maintains the cells in a quiescent state. However, to facilitate platelet activation at sites of vascular injury the inhibitory effects of basal cAMP signaling must be overcome. Upon activation, platelets generate and release soluble factors that act in a paracrine fashion to promote platelet activation through the inhibition of cAMP signaling. Platelet-derived adenosine diphosphate (ADP) inhibits AC activity through binding to Gαi-coupled P2Y~12~ that blocks cAMP synthesis. Simultaneously, thrombin and thrombospondin-1 activate PDE3A, leading to reduced intracellular cAMP ([@B15]; [@B46]; [@B30]). Together, these mechanisms act to reduce the threshold for platelet activation and ensure rapid recruitment of platelets to vascular lesions. An imbalance in this dynamic system can have profound effects on platelets function as exemplified by several recently identified congenital disorders that affect cAMP production ([@B16]). A Gαs hypofunction mutation is associated with platelet hyperactivity ([@B13]). Conversely, a Gαs gain-of-function mutation is reported to lead to a trauma-related bleeding tendency ([@B14]). Consistent with these observations, a recently identified mutation in the gene encoding the catalytic subunit of PKA leads to macrothrombocytopenia with the homozygous patients showing a bleeding tendency ([@B23]). The control of cAMP signaling and therefore the phosphorylation of key PKA substrates is mediated by both protein phosphatases and several PDEs through the hydrolysis of cAMP into 5′-AMP. Platelets express two cAMP hydrolysing enzymes, PDE2A and PDE3A ([@B9]; [@B36]; [@B31]). However, the phosphatases that dephosphorylate PKA substrates are unknown. Thus, platelets possess a complex cAMP signaling network that includes multiple isoforms of AC, PKA and PDE (Figure [1A](#F1){ref-type="fig"}), but molecular control and integration of this network is required to maintain the balance between haemostasis and thrombosis.

![**(A)** Model for the control of platelet function by cAMP signaling in platelets. Segregated pools of cAMP are formed by the individual isoforms of AC. The cAMP generated may target individual PKA isoforms. AKAPs act to focus isoform specific PKA activity to individual substrates that are linked to distinct platelet functions. The AKAPs may also act to localize PDE isoforms in manner that controls specific signaling events. **(B)** PKA substrates are differentially distributed and targeted by PKA in an AKAP-dependent manner. Washed platelets (5 × 10^8^/mL) were left untreated or pre-treated for 60 min with RIAD-Arg~11~ (2 μM) or stHt31 (2 μM), which target PKA-I and PKA-II specific AKAPs respectively, followed by PGI~2~ (50 nM) for 1 min. Platelets were lysed then subjected into subcellular fractionation (20,000 × *g*, 90 min at 4°C) to separate platelet membranes. Membrane and cytosol fractions (20 μg) were analyzed by SDS-PAGE and immunoblotting using phosphoPKA substrate antibody and integrin β as a membrane marker. Blots are representative of three independent experiments. Membranes were visualized using enhanced chemiluminescence. Red and blue arrows represent AKAP sensitive bands in membrane and cytosolic bands respectively.](fphar-06-00266-g0001){#F1}

Spatiotemporal Regulation of cAMP Signaling---the Role of AKAPs
===============================================================

The spatiotemporal control of cAMP signaling is influenced by the opposing functions of localized AC and PDE isozymes and the scaffolding properties of A-kinase anchoring proteins (AKAPs). The cAMP signal is conveyed through assembly of macromolecules that constrain cAMP signaling to specific regions in the cell. The formation of multiple cAMP signaling hubs where individual isoforms of PKA interact with anchoring proteins that focus PKA activity on specific substrates, allows the control of specific biological functions in response to distinct stimuli ([@B41]; [@B37]; [@B40]). Early studies reported that PKA substrates were specifically localized in distinct subcellular compartments of blood platelets ([@B10], [@B11]). Our own studies support these observations with distinct phospho-PKA substrates found in cytosolic and membrane fractions of platelets (Figure [1B](#F1){ref-type="fig"}). Consistent with the detection of PKA substrates in multiple cell compartments we found using both subcellular fractionation and immunostaining experiments that PKA-I and PKA-II are differentially localized in platelets. PKA-RI was found primarily at the cell periphery, while PKA-RII was clustered within the cytosol ([@B27]). We found that membrane lipid rafts allow for further compartmentalization of cAMP signaling in platelets. For example, a pool of AC isoform 5/6 and PKA-I, but not PKA-II, are localized to these membrane micro-domains in platelets where the rafts act to constrain PKA activity ([@B28]). Thus, PKA signaling in platelets, like T-cells, dendritic cells and cardiomyocytes is compartmentalized to membrane fractions in close proximity to the site of cAMP generation ([@B33]; [@B8]; [@B35]; [@B3]). The question then arises as to how these cAMP signaling compartments are organized and configured in platelets. An elegant study using a chemical proteomic approach indicated the presence of localized and active cAMP signaling nodes, which were dynamic in nature with PKA activity changing within distinct signaling complexes in response to platelet activation.The formation of these complexes was attributed to the presence of several AKAPs, although the precise composition of these complexes or how they were convened was not extrapolated ([@B24]). AKAPs are structurally diverse scaffolding proteins that interact with PKA and target it to a specific subcellular compartment through a unique targeting domain. All AKAPs possess a highly conserved PKA binding domain. This is an amphipathic helix, which can bind to the docking and dimerization domain (D/D domain) of the PKA regulatory homodimer ([@B6]; [@B20]; [@B34]). While AKAPs specifically bind PKA, they can act as hubs that coalesce other signaling components including kinases, phosphatases, PDEs, ACs, and even receptors. The assembly of such macromolecules act as signal switches that are intricately regulated spatially and temporally by signal initiators and terminators. Over fifty AKAPs have now been identified and of these fifteen are potentially expressed in platelets ([@B24]; [@B32]; [@B4]). Given the potential complexity within the cAMP signaling system, it is likely that AKAPs play a key role in the control of platelet function by cAMP (Figure [1A](#F1){ref-type="fig"}). Unfortunately, the study of AKAPs in platelets has been limited by an inability to apply standard molecular biology approaches used to characterize AKAPs in many other cells. However, he development of cell permeable disruptor peptides that mimic the sequence of the amphipathic helix of the PKA binding domain and target PKA-AKAP interactions in an isoform-specific manner has allowed us to begin examine this hypothesis ([@B5]; [@B18]; [@B45]). These peptides can displace PKA from multi-protein complexes formed by AKAPs allowing the functional relevance of these AKAPs to be evaluated. Focusing on PKA-I we used RI-anchoring disruptor peptide or RIAD-Arg~11~ to demonstrate that a number of cAMP signaling events in platelets were dependent on PKA-I-AKAP interactions ([@B5]).Examining PKA signaling events using immunoblotting following subcellular fractionation, we were able to observe a decrease in the intensity of PKA phosphorylation events after stimulating with PGI~2~ in the presence of RIAD-Arg~11~ in both membrane and cytosolic fractions when compared with PGI~2~ alone suggesting that PGI~2~ trigger PKA-I-specific signaling events that are AKAP-dependent in platelets (Figure [1B](#F1){ref-type="fig"}). This was followed by a number of specialized assays, including aggregation, secretion and spreading to evaluate the role of PKA-I-AKAPs interactions in the inhibitory effect of prostacyclin on platelet function (Figure [2](#F2){ref-type="fig"}). As expected collagen-induced platelet aggregation was inhibited by PGI~2~, but the inhibitory action was diminished significantly by the presence of RIAD-Arg~11~ (Figure [2A](#F2){ref-type="fig"}). The secretion of dense granules is a major factor in potentiating platelet aggregation in response to collagen.Luminescence assays demonstrated that PGI~2~ abolished the secretion of ATP from these granules in response to collagen, but again the presence of RIAD-Arg~11~ reversed its inhibitory effects (Figure [2B](#F2){ref-type="fig"}). Finally platelets were adhered to immobilized collagen to induce a physiological spreading response. In response to collagen, platelets extended filopodia and lamellipodium consistent with spreading (Figure [2C](#F2){ref-type="fig"}). The presence of PGI~2~ prevented the spreading response without influencing the ability of platelets to adhere. However, pre-treating platelets with RIAD-Arg~11~, allowed platelets to adhere and spread on collagen. Interestingly, in all assays, RIAD-Arg~11~ failed to cause a full recovery from the inhibitory effects, with the remaining effects of cAMP potentially caused by PKA-II, which would be insensitive to the effects of RIAD. While the data produced using the peptides should be interpreted with caution, our observations suggest that PKA-I-AKAP interactions are required for optimal PGI~2~ inhibition of collagen-induced platelet activation and that PKA-I and PKA-II have non-redundant roles in human platelets.

![**Inhibition of platelet activity by prostacyclin (PGI~2~) requires PKA-I/AKAP interactions. (A)** Washed platelets (2.5 × 10^8^/ml) were left untreated or pre-incubated with RIAD-Arg~11~ (2 μM) or scrRIAD-Arg~11~ (2 μM) for 1 h followed by addition of PGI~2~ (50 nM) for 1 mine and then stimulated with collagen (5 μg/ml) for 4 min under stirring conditions. (Ai) representative aggregation traces. (Aii) Collated data of four independent experiments expressed as mean ± SEM. ± *p* \< 0.01 compared to absence of PGI~2~; \**p* \< 0.05 compared to PGI~2~ alone. **(B)** As in (A) except platelet ATP secretion was measured by the signal released by a Luciferin-Luciferase reaction using a Chrono-log Lumi-aggregometer. (Bi) representative ATP secretion traces. (Bii) Collated data of four independent experiments expressed as mean ± SEM. ±*p* \< 0.01 compared to absence of PGI~2~; \**p* \< 0.05 compared to PGI~2~ alone. **(C)** Washed platelets (5 × 10^7^/ml) were placed on human serum (i) or collagen-coated coverslips (50 μg/ml) (ii--iv) for 60 min at 37°C in the absence (ii) or presence (ii) PGI~2~ (100 nM). In (iv) washed platelets were first pre-treated with RIAD-Arg~11~ (2 μM) for 1 h followed by addition of PGI~2~ (100 nM). At the end of the incubation period, non-adherent platelets were removed by washing with PBS. The remaining adherent platelets were fixed, permeabilized with 0.1% Triton, and stained for F-action with TRITC-conjugated phalloidin then visualized with fluorescence microscope. Scale bar is 5 μm.](fphar-06-00266-g0002){#F2}

The signaling events driven by compartmentalisation of PKA isoforms are finessed by the PDEs ([@B31]). Using FRET, [@B21] demonstrated that distinct pools of cAMP could be shaped by specifically localized PDE isoforms ([@B21]; [@B40]). While the subcellular localisation of platelet PDEs is not clear there is evidence for potential non-redundant roles in controlling cAMP signaling. Pharmacological inhibition of PDE2A resulted in increased basal cAMP, while inhibition of PDE3A blocked platelet aggregation, reduced Ca^2+^ mobilization and increased vasodilator stimulated phosphoprotein (VASP) phosphorylation ([@B12]). These data suggest PDE2A and PDE3A play non-redundant roles, whereby the former controls elevated cAMP levels and the latter maintains a threshold of cAMP levels in pools that control integrin activation and Ca^2+^ mobilization. Interestingly, PKA has been shown to phosphorylate and activate of PDE3A in platelets ([@B22]; [@B19]), suggesting a feedback regulatory mechanism within platelets to control cAMP signaling. The molecular composition of this feedback regulatory complex is ill-defined, although preliminary data in our laboratory suggests that phosphorylation of PDE3A is performed by PKA-II in an AKAP-dependent manner (Law and Naseem, unpublished). The localisation of PDE isoforms to specific signaling complexes and PKA substrates is a key area for further characterisation of cAMP signaling in platelets.

Evidence of Functional AKAPs in Platelets
=========================================

The concept of isoform-specific PKA substrates in platelets that are regulated by an AKAP is an attractive one, although evidence for their functional roles is still lacking. Platelet AKAPs as reported in proteomic and transcriptome studies include AKAP1, AKAP2, AKAP7(γ), AKAP9, AKAP10, AKAP11, AKAP13, moesin, ezrin, Rab32, BIG2 (brefeldin-A-inhibited guanine-nucleotideexchange protein 2), WAVE-1 (Wiskott--Aldrich syndrome protein verprolin homologous 1), MAP2 (microtubuleassociated protein 2), smAKAP (small-membrane AKAP) and neurobeachin. Of those fifteen AKAPs we were able to verify the presence of several by immunoblotting techniques. To the best of our knowledge only two functional AKAPs have been identified in platelets, small membrane AKAP (smAKAP) and moesin. SmAKAP was identified in platelets and cardiomyocytes by using chemical proteomics. This AKAP specifically targets PKA-I to cellular membrane through myristoylation and palmitoylation anchors ([@B3]). Verification of the presence of smAKAP by immunoblotting and its functional role is yet to be determined in platelets. Using a combination of cAMP pull-down, immunoblotting and kinase assays we reported recently that moesin targets PKA-I into platelet lipid rafts where it can phosphorylate its physiological substrate GPIbβ ([@B27]). This phosphorylation event contributes to the inhibition of platelet-driven thrombus formation to the adhesive protein von Willebrand factor. This data identifies moesin as the first functionally validated AKAP in platelets, but also indicate GPIbβ as the first PKA-I-specific substrate in platelets. Interestingly, we observed multiple phosphoproteins in platelet lipid rafts that were sensitive to the localisation of PKA-I suggesting that these microdomains may focus PKA-I on several targets required for regulation of platelet function by cAMP. These two studies provide an insight into the potential compartmentalization of cAMP signaling by AKAPs, although more work is required to understand the composition and dynamics of AKAP-regulated macromolecules in platelets.

Perspective
===========

The cAMP signaling pathway represents the most potent endogenous system for the control of platelet activation through its ability to modulate multiple platelet functions. However, the molecular mechanisms by which cAMP/PKA signaling controls individual platelet functions are unclear. Fundamental to elucidating this issue is an improved understanding of the organization and spatial resolution of the downstream effectors of cAMP in platelets. Emerging data suggests that compartmentalization of key cyclic nucleotide signaling complexes may control aspects of platelet function as evident by the identification of a localized PKG1β-IP~3~R1-IRAG-PDE5 complex that regulate calcium release in response to NO ([@B43]). The challenge for platelet biologists is to determine whether this multi-protein complex model can be extended to the cAMP pathway. The advances in both transcriptomics and proteomics have now identified a number of AKAPs that potentially provide spatial resolution and specificity to PKA-mediated phosphorylation events. Our data demonstrating differential localization of PKA-I and PKA-II and compartmentalization of PKA-I by the AKAP moesin to target a specific substrate provide proof of principle that the AKAP hypothesis can be translated to platelets. Interestingly, we have found that the catalytic subunit of PKA is constitutively associated with RhoA ([@B1]), PDE3A and IP~3~R1 through AKAP-dependent mechanisms (unpublished), suggesting the presence of numerous individual PKA-AKAP complexes. Unfortunately, platelet research in this area is hampered by an inability to apply conventional gene silencing or overexpression technologies and therefore relies on the identification of native complexes through protein purification. As protein purification techniques become more sensitive, the ability to identify and characterize native complexes increases and may allow functional relevance to be established. Our data with cell permeable disruptor peptides provide one approach to address this issue. However, these peptides are limited in their specificity and only allow resolution of isoform-specific signaling and functional events. Future lines of investigation could involve the identification of individual PKA-AKAP complexes and the application of a new generation of peptide disruptors that discriminate between individual PKA-AKAP complexes ([@B17]). An important resource for the functional assessment of AKAPs in platelets is genetically modified mice. In the absence of standard molecular biology approaches, mice offer a strategy for examining the role of specific PKA-AKAP complexes on haemostasis and thrombosis *in vivo*. For example, mice heterozygous for Neurobeachin, an established AKAP ([@B42]), demonstrated altered PKA phosphorylation profile and abnormal platelet dense granules ([@B25]). Detailed examination of platelet sensitivity to cAMP of such mice and their use in adoptive transfer protocols are likely to be key tools for future evaluation of specific PKA-AKAP complexes in the physiological control of platelet function.

The original AKAP hypothesis has now evolved beyond simple anchoring of PKA signaling, with identification of numerous other signaling moieties including phosphatases, PDEs and other kinases coalescing into the complexes ([@B44]; [@B38]). Moreover, these multi-protein signaling hubs are extremely dynamic in nature and have been shown to be both tissue and substrate specific. This particular concept has a specific relevance for platelets where cAMP signaling needs to respond to physiological stimuli that promote platelet activation. Indeed, it may be that the dynamic adjustment of these complexes, in response to agents that promote cAMP generation and platelet agonists, is what determines the threshold for platelet activation and allows effective haemostasis while preventing thrombosis. We believe that the identification of platelet AKAPs through proteomics provides the platform for new lines of investigation in establishing the spatial and temporal organization of cAMP signaling in platelets and how this intersects with platelet activatory signaling.
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